Browse by Audience
Skip to content
Papers of the Week
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures.
Abstract
Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment of migraine. Galcanezumab demonstrated early onset of effect in patients with migraine but it is unknown whether the same holds true for patients who have not benefited from multiple prior migraine preventives.